Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy and tolerability of isocitrate dehydrogenase inhibitors in patients with acute myeloid leukemia: A systematic review of clinical trials.

Leukemia research - 1 Jun 2023

Aiman Wajeeha, Ali Muhammad Ashar, Basit Muhammad Abdul, Omar Zainab, Suleman Muhammad, Hassan Muhammad, Jamil Taimoor, Anwar Muhammad Saad, Shafique Zubair, Dhanesar Gurneel, Faisal Muhammad Salman, Akerman Michael J, Maroules Michael, Anwer Faiz

Abstract excerpt

BACKGROUND: Acute myeloid leukemia (AML) is a hematological malignancy due to anomalous differentiation and proliferation of hematopoietic stem cells with myeloid blast buildup. Induction chemotherapy is considered the first line of treatment in most patients with AML. However, targeted therapy in the form of FLT-3, IDH, BCL-2, and immune checkpoint inhibitors, can be considered as the first line depending on...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Azacitidine
Share to Enzyme Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Isocitrate Dehydrogenase

Share to Leukemia, Myeloid, Acute

Share to Multicenter Studies as Topic

Share to Mutation

Source

Identifiers

PMID: 37100025
DOI: 10.1016/j.leukres.2023.107077

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy and tolerability of isocitrate dehydrogenase inhibitors in patients with acute myeloid leukemia: A systematic review of clinical trials.PMID 37100025Read ↗

Isocitrate Dehydrogenase Inhibitors in Acute Myeloid Leukemia.Semantic proximity Read ↗

A review of the isocitrate dehydrogenase inhibitors in management of adult patients with AML and MDS.Semantic proximity Read ↗

Efficacy and safety of FDA-approved IDH inhibitors in the treatment of IDH mutated acute myeloid leukemia: a systematic review and meta-analysis.Semantic proximity Read ↗

Long-term remission and survival in older adults with IDH-mutated acute myeloid leukemia treated with IDH inhibitors.Semantic proximity Read ↗

Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.Semantic proximity Read ↗

IDH Inhibitors in AML-Promise and Pitfalls.Semantic proximity Read ↗

Acute myeloid leukemia treatment outcomes with isocitrate dehydrogenase mutations: A systematic review and meta-analysis.Semantic proximity Read ↗

Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.Semantic proximity Read ↗

Evaluating ivosidenib for the treatment of acute myeloid leukemia.Semantic proximity Read ↗

Clinical Implications of Isocitrate Dehydrogenase Mutations and Targeted Treatment of Acute Myeloid Leukemia with Mutant Isocitrate Dehydrogenase Inhibitors-Recent Advances, Challenges and Future Prospects.Semantic proximity Read ↗

The Molecular Mechanisms of Resistance to IDH Inhibitors in Acute Myeloid LeukemiaSemantic proximity Read ↗

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.